Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study is to investigate the prognostic value of lymph node (LN) ratio (LNR) in patients with breast cancer after neoadjuvant chemotherapy. Materials and Methods This retrospective analysis is based on the data of 814 patients with stage II/III breast cancer treated with four cycles of doxorubicin/cyclophosphamide followed by four cycles of docetaxel before surgery. We evaluated the clinical significance of LNR (3 categories: low 0-0.20 vs. intermediate 0.21-0.65 vs. high 0.66-1.00) using a Cox proportional regression model. Results A total of 799 patients underwent breast surgery. Pathologic complete response (pCR, ypT0/isN0) was achieved in 129 patients (16.1%) (hormone receptor [HR] +/human epidermal growth factor receptor 2 [HER2] –, 34/373 [9.1%]; HER2+, 45/210 [21.4%]; triple negative breast cancer, 50/216 [23.1%]). The mean numbers of involved LN and retrieved LN were 2.70 (range, 0 to 42) and 13.98 (range, 1 to 64), respectively. The mean LNR was 0.17 (low, 574 [71.8%]; intermediate, 170 [21.3%]; high, 55 [6.9%]). In univariate analysis, LNR showed significant association with a worse relapse-free survival (3-year relapse-free survival rate 84.8% in low vs. 66.2% in intermediate vs. 54.3% in high; p < 0.001, log-rank test). In multivariate analysis, LNR did not show significant association with recurrence after adjusting for other clinical factors (age, histologic grade, subtype, ypT stage, ypN stage, lymphatic or vascular invasion, and pCR). In subgroup analysis, the LNR system had good prognostic value in HR+/HER2– subtype. Conclusion LNR is not superior to ypN stage in predicting clinical outcome of breast cancer after neoadjuvant chemotherapy. However, the prognostic value of the LNR system in HR+/HER2– patients is notable and worthy of further investigation.
Abstract
Purpose The purpose of this study is to investigate the prognostic value of lymph node (LN) ratio (LNR) in patients with breast cancer after neoadjuvant chemotherapy. Materials and Methods This retrospective analysis is based on the data of 814 patients with stage II/III breast cancer treated with four cycles of doxorubicin/cyclophosphamide followed by four cycles of docetaxel before surgery. We evaluated the clinical significance of LNR (3 categories: low 0-0.20 vs. intermediate 0.21-0.65 vs. high 0.66-1.00) using a Cox proportional regression model. Results A total of 799 patients underwent breast surgery. Pathologic complete response (pCR, ypT0/isN0) was achieved in 129 patients (16.1%) (hormone receptor [HR] +/human epidermal growth factor receptor 2 [HER2] –, 34/373 [9.1%]; HER2+, 45/210 [21.4%]; triple negative breast cancer, 50/216 [23.1%]). The mean numbers of involved LN and retrieved LN were 2.70 (range, 0 to 42) and 13.98 (range, 1 to 64), respectively. The mean LNR was 0.17 (low, 574 [71.8%]; intermediate, 170 [21.3%]; high, 55 [6.9%]). In univariate analysis, LNR showed significant association with a worse relapse-free survival (3-year relapse-free survival rate 84.8% in low vs. 66.2% in intermediate vs. 54.3% in high; p < 0.001, log-rank test). In multivariate analysis, LNR did not show significant association with recurrence after adjusting for other clinical factors (age, histologic grade, subtype, ypT stage, ypN stage, lymphatic or vascular invasion, and pCR). In subgroup analysis, the LNR system had good prognostic value in HR+/HER2– subtype. Conclusion LNR is not superior to ypN stage in predicting clinical outcome of breast cancer after neoadjuvant chemotherapy. However, the prognostic value of the LNR system in HR+/HER2– patients is notable and worthy of further investigation.
참고문헌 (24)
- Fisher B, "Effect of preoperative chemotherapy on the outcome of women with operable breast cancer", J Clin Oncol, 16, pp.2672~2685 (1998)
- Bear HD, "Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer : National Surgical Adjuvant Breast and Bowel Project Protocol B-27", J Clin Oncol, 24, pp.2019~2027 (2006)
- van der Hage JA, "Preoperative chemotherapy in primary operable breast cancer : results from the European Organization for Research and Treatment of Cancer trial 10902", J Clin Oncol, 19, pp.4224~4237 (2001)
- Cortazar P, "Pathological complete response and longterm clinical benefit in breast cancer : the CTNeoBC pooled analysis", Lancet, 384, pp.164~172 (2014)
- Kuerer HM, "Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer", Am J Surg, 176, pp.502~509 (1998)
- Pierga JY, "Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer", Br J Cancer, 83, pp.1480~1487 (2000)
- Symmans WF, "Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy", J Clin Oncol, 25, pp.4414~4422 (2007)
- Colleoni M, "A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer", Ann Oncol, 20, pp.1178~1184 (2009)
- Neuman H, "Axillary lymph node count is lower after neoadjuvant chemotherapy", Am J Surg, 191, pp.827~829 (2006)
- Erbes T, "Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection", BMC Cancer, 14, pp.4~ (2014)
- Woodward WA, "Prognostic value of nodal ratios in node-positive breast cancer", J Clin Oncol, 24, pp.2910~2916 (2006)
- Vinh-Hung V, "Lymph node ratio as an alternative to pN staging in node-positive breast cancer", J Clin Oncol, 27, pp.1062~1068 (2009)
- Danko ME, "Improved staging in node-positive breast cancer patients using lymph node ratio : results in 1, 788 patients with longterm follow-up", J Am Coll Surg, 210, pp.797~805 (2010)
- Ahn SH, "Lymph node ratio and pN staging in patients with nodepositive breast cancer: a report from the Korean breast cancer society", Breast Cancer Res Treat, 130, pp.507~515 (2011)
- Dings PJ, "The prognostic value of lymph node ratio in node-positive breast cancer : a Dutch nationwide population-based study", Ann Surg Oncol, 20, pp.2607~2614 (2013)
- Liu D, "Lymph node ratio and breast cancer prognosis : a meta-analysis", Breast Cancer, 21, pp.1~9 (2014)
- Keam B, "Clinical significance of axillary nodal ratio in stage II", III breast cancer treated with neoadjuvant chemotherapy, 2009, pp.116, 153~160
- Saxena N, "Prognostic value of axillary lymph node status after neoadjuvant chemotherapy : results from a multicentre study", Eur J Cancer, 47, pp.1186~1192 (2011)
- Chen S, "Lymph node counts and ratio in axillary dissections following neoadjuvant chemotherapy for breast cancer : a better alternative to traditional pN staging", Ann Surg Oncol, 21, pp.42~50 (2014)
- von Minckwitz G, "Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes", J Clin Oncol, 30, pp.1796~1804 (2012)
- Lips EH, "Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response", Breast Cancer Res Treat, 140, pp.63~71 (2013)
- Tausch C, "Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group(ABCSG)", Ann Surg Oncol, 19, pp.1808~1817 (2012)
- Goldhirsch A, "Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011", Ann Oncol, 22, pp.1736~1747 (2011)
- Sestak I, "Factors predicting late recurrence for estrogen receptor-positive breast cancer", J Natl Cancer Inst, 105, pp.1504~1511 (2013)